henhaobio
Sign in

bioRxivMicrobiology

Human gut bifidobacteria inhibit the growth of the opportunistic fungal pathogen Candida albicans

L. Ricci, J. Mackie, G. E. Donachie, A. Chapuis, K. Mezerova, M. D. Lenardon, A. J. Brown, S. H. Duncan, A. W. Walker

PDFDOIPreprint

Abstract

The human gut microbiota protects the host from invading pathogens and the overgrowth of indigenous opportunistic species via mechanisms such as competition for nutrients and by production of antimicrobial compounds. Here, we investigated the antagonist activity of human gut bacteria towards Candida albicans, an opportunistic fungal pathogen that can cause severe infections and mortality in susceptible patients. Co-culture batch incubations of C. albicans in the presence of faecal microbiota from six different healthy individuals revealed varying levels of inhibitory activity against C. albicans. 16S rRNA gene sequence profiling of these faecal co-culture bacterial communities showed that the Bifidobacteriaceae family, and Bifidobacterium adolescentis in particular, were most correlated with antagonistic activity against C. albicans. Follow up mechanistic studies confirmed that culture supernatants of Bifidobacterium species, particularly B. adolescentis, inhibited C. albicans in vitro under both aerobic and anaerobic conditions. Production of the fermentation acids acetate and lactate, together with the concomitant decrease in pH, were strong drivers of the inhibitory activity. Bifidobacteria may therefore represent attractive targets for the development of probiotics and prebiotic interventions tailored to enhance inhibitory activity against C. albicans in vivo.

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISKralova '24Mishra '26Thangamani '18Kunyeit '20Kapitan '25Mathew '25
75% semantic matchImmunology
J. S. Kralova, C. Donic, B. Dassa+21 more·Journal of Experimental Medicine·Mar 18, 2024